These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Characterization of systemic amyloid deposits by mass spectrometry. Murphy CL; Wang S; Williams T; Weiss DT; Solomon A Methods Enzymol; 2006; 412():48-62. PubMed ID: 17046651 [TBL] [Abstract][Full Text] [Related]
26. LECT-2 amyloidosis: what do we know? Mann BK; Bhandohal JS; Cobos E; Chitturi C; Eppanapally S J Investig Med; 2022 Feb; 70(2):348-353. PubMed ID: 34848562 [TBL] [Abstract][Full Text] [Related]
27. Protein profiling of isolated uterine AA amyloidosis causing fetal death in goats. Gaffney PM; Barr B; Rowe JD; Bett C; Drygiannakis I; Giannitti F; Trejo M; Ghassemian M; Martin P; Masliah E; Sigurdson CJ FASEB J; 2015 Mar; 29(3):911-9. PubMed ID: 25422367 [TBL] [Abstract][Full Text] [Related]
28. [New Insights into Diagnosis and Pathogenesis of Amyloidosis by Mass Spectrometric Analysis]. Tasaki M; Obayashi K; Ando Y Rinsho Byori; 2016 Jun; 64(6):675-679. PubMed ID: 30695322 [TBL] [Abstract][Full Text] [Related]
29. A Proteomic Atlas of Cardiac Amyloid Plaques. Kourelis TV; Dasari SS; Dispenzieri A; Maleszewski JJ; Redfield MM; Fayyaz AU; Grogan M; Ramirez-Alvarado M; Abou Ezzeddine OF; McPhail ED JACC CardioOncol; 2020 Nov; 2(4):632-643. PubMed ID: 33511353 [TBL] [Abstract][Full Text] [Related]
30. Proteomics in molecular diagnosis: typing of amyloidosis. Loo D; Mollee PN; Renaut P; Hill MM J Biomed Biotechnol; 2011; 2011():754109. PubMed ID: 22131817 [TBL] [Abstract][Full Text] [Related]
31. Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing. Lavatelli F; Merlini G Proteomics; 2018 Apr; 18(7):e1700353. PubMed ID: 29389069 [TBL] [Abstract][Full Text] [Related]
32. Twists and turns of determining amyloid type and amyloid-related organ damage: discordance and clinical skepticism in the era of proteomic typing. Kaul E; Pilichowska M; Vullaganti M; Madan N; Comenzo RL Amyloid; 2014 Mar; 21(1):62-5. PubMed ID: 24256111 [TBL] [Abstract][Full Text] [Related]
33. Classification of Amyloidosis by Model-Assisted Mass Spectrometry-Based Proteomics. Palstrøm NB; Rojek AM; Møller HEH; Hansen CT; Matthiesen R; Rasmussen LM; Abildgaard N; Beck HC Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008745 [TBL] [Abstract][Full Text] [Related]
34. A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. Gilbertson JA; Theis JD; Vrana JA; Lachmann H; Wechalekar A; Whelan C; Hawkins PN; Dogan A; Gillmore JD J Clin Pathol; 2015 Apr; 68(4):314-7. PubMed ID: 25637636 [TBL] [Abstract][Full Text] [Related]
35. Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Dasari S; Theis JD; Vrana JA; Rech KL; Dao LN; Howard MT; Dispenzieri A; Gertz MA; Hasadsri L; Highsmith WE; Kurtin PJ; McPhail ED Mayo Clin Proc; 2020 Sep; 95(9):1852-1864. PubMed ID: 32861330 [TBL] [Abstract][Full Text] [Related]
36. Advances in clinical applications of tissue proteomics: opportunities and challenges. Dogan A Expert Rev Proteomics; 2014 Oct; 11(5):531-3. PubMed ID: 25187078 [TBL] [Abstract][Full Text] [Related]
37. [Characterization of amyloidosis]. Yazaki M; Ikeda S Brain Nerve; 2014 Jul; 66(7):723-30. PubMed ID: 24998817 [TBL] [Abstract][Full Text] [Related]
38. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis. Picken MM Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228 [TBL] [Abstract][Full Text] [Related]